SVA

科兴生物
NASDAQ

实时行情|Nasdaq Last Sale

6.47
0.00
0.00%
停牌 16:00 04/24 EDT
开盘
--
昨收
6.47
最高
--
最低
--
成交量
--
成交额
--
52周最高
6.58
52周最低
6.25
市值
6.40亿
市盈率(TTM)
27.35
分时
5日
1月
3月
1年
5年

SVA 新闻

更多
China's Sinopharm to test potential COVID-19 vaccine in Brazil
Reuters · 4天前
我们何时能够获得新冠疫苗?四大疫苗最有希望 临床面临伦理考验
智通财经网 · 07/27 10:53
未名医药遇到麻烦了:股份被司法冻结财务报表被出具“非标”意见
东方财富网 · 07/24 01:46
China's Sinopharm says coronavirus vaccine could be ready by year-end - state media
A coronavirus vaccine candidate developed by China National Pharmaceutical Group (Sinopharm) could be ready for public use by the end of this year, state media reported on Wednesday, ahead of a previous expectation it may become available in 2021. Sinopharm C
Reuters · 07/23 07:07
疫情不断恶化,美股盘前走低!阿里盘前涨超4%,蚂蚁集团上市计划出炉
腾讯证券 · 07/20 10:32
Bangladesh allows late-stage trial of China's Sinovac COVID-19 vaccine
Bangladesh has approved the third-phase trial of a potential COVID-19 vaccine developed by China's Sinovac Biotech Ltd, officials said on Monday, as infections continue to rise in the densely-populated South Asian country. Sinovac has been looking for volunte
Reuters · 07/20 06:29
Russia may start Phase III trial of COVID-19 vaccine in mid-August - RIA
A Russian institute developing one of the country's potential coronavirus vaccines hopes to start its final stage testing in a small section of the general public in mid-August, the RIA news agency cited the institute's director as saying on Monday. Globally,
Reuters · 07/13 13:56
Thailand plans Nov human testing for potential coronavirus vaccine
Thai researchers plan to begin human trials of a potential vaccine for the new coronavirus in November and are preparing 10,000 doses, a senior official said on Sunday, aiming for a vaccine that could be ready for use by late next year. Following favourable r
Reuters · 07/12 06:14

所属板块

制药
+1.48%
制药与医学研究
+1.92%

热门股票

代码
价格
涨跌幅

SVA 简况

科兴控股生物技术有限公司(简称科兴)是一家生物制药控股公司。该公司主要负责研究、开发、制造和商业化针对甲型肝炎、乙型肝炎、季节性流感、血凝素5神经氨酸酶1(H5N1)和甲型流感(H1N1)大流行性流感和腮腺炎等人类传染病的疫苗。该公司的产品包括在中国处于临床和临床前发展阶段的候选疫苗。该公司主要从事传染疾病疫苗的销售、营销、制造和开发。该公司开发多种产品,包括Healive、Bilive、Anflu、Panflu、Whole Viron大流行性流感疫苗、Split Viron大流行流感疫苗、Panflu.1、RabEnd、腮腺炎疫苗、肠道病毒71(EV71)疫苗、肺炎球菌多糖疫苗、肺炎球菌结合疫苗、风疹疫苗、水痘疫苗和Sabin灭活脊髓灰质炎疫苗等。
展开

微牛提供Sinovac Biotech Ltd.(NASDAQ-SVA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的SVA股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易SVA股票基本功能。